BioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Down 6.4% in March

Cornelia Mascio
Mag 6, 2017

Piper Jaffray Companies reissued an "overweight" rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, February 13th. (NASDAQ:BCRX) has risen 35.92% since September 27, 2016 and is uptrending. It has outperformed by 34.68% the S&P500.

Davidson Investment Advisors increased First Republic Bank San Francisco Ca (FRC) stake by 2.85% reported in 2016Q4 SEC filing. The Rtw Investments Llc holds 4.08 million shares with $25.82M value, down from 4.20M last quarter.

The stock decreased 1.35% or $0.25 during the last trading session, reaching $18.29. Zebra Technologies Corp. (NASDAQ:ZBRA) has risen 35.01% since September 28, 2016 and is uptrending. It has outperformed by 9.49% the S&P500. Vanguard Group invested in 0% or 3.36 million shares. 19 funds opened positions while 32 raised stakes. Ra Cap Mngmt Ltd Company reported 2.99M shares. Comml Bank Of America Corp De stated it has 17,461 shares. About shares traded. BioCryst Pharmaceuticals, Inc. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post ($0.68) EPS for the current fiscal year. (NASDAQ:BCRX). Dafna Capital Mgmt Limited Co reported 65,900 shares. Jpmorgan Chase has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Great West Life Assurance Can reported 0% stake. 10,838 are held by Arrowpoint Asset Management Lc.

02/28/2017 - BioCryst Pharmaceuticals, Inc. had its " rating reiterated by analysts at Jefferies. (NASDAQ:BCRX) moved to around 99.18. Credit Suisse Ag accumulated 64,633 shares. BioCryst Pharmaceuticals posted earnings of ($0.31) per share during the same quarter last year, which would indicate a positive year over year growth rate of 38.7%. At present, 0 analysts call it Sell, while 12 think it is Hold. JP Morgan downgraded the shares of BCRX in report on Tuesday, February 9 to "Neutral" rating. Closely-held shares are those owned by insiders, major shareholders and employees, while restricted stock refers to insider shares that can not be traded because of a temporary restriction such as the lock-up period after an initial public offering.

Since December 19, 2016, it had 0 insider buys, and 5 sales for $163,996 activity.

In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 3,250 shares of the firm's stock in a transaction that occurred on Monday, March 20th.

According to the most recent research notes issued by analysts 9 analysts have outstanding research reports on BioCryst Pharmaceuticals, Inc. Therefore 67% are positive. BioCryst Pharmaceuticals has $16 highest and $2 lowest target. $7.43's average target is 14.84% above currents $6.47 stock price. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/05/04/biocryst-pharmaceuticals-inc-bcrx-raised-to-buy-at-zacks-investment-research.html. The rating was upgraded by Piperjaffray to "Overweight" on Friday, August 12. FBR Capital maintained BioCryst Pharmaceuticals, Inc. Also, there are 0 buy, 1 sell and 0 strong sell ratings, collectively assigning a 1.78 average brokerage recommendation. Ladenburg Thalmann Financial Services initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Thursday, February 16th. Geode Mngmt Llc invested 0% in BioCryst Pharmaceuticals, Inc. The stock has "Buy" rating by Jefferies on Monday, April 3. Bank of America initiated Penumbra Inc (NYSE:PEN) on Wednesday, October 14 with "Buy" rating. The company was downgraded on Thursday, August 4 by JMP Securities. As per Friday, August 12, the company rating was upgraded by PiperJaffray.

02/09/2016 - BioCryst Pharmaceuticals, Inc. had its " rating reiterated by analysts at Rodman & Renshaw. (NASDAQ:BCRX) for 1,801 shares. Envestnet Asset owns 119 shares.

Investors sentiment increased to 0.99 in Q4 2016. Its up 0.24, from 0.75 in 2016Q3. It increased, as 45 investors sold AET shares while 289 reduced holdings. D E Shaw reported 304,015 shares. Sei Invs holds 153,893 shares or 0.09% of its portfolio. Federated Invsts Pa holds 0.04% or 106,979 shares. The company's market capitalization is $481.45 million. Meritage LP stated it has 0.02% in Aetna Inc (NYSE:AET). Hightower Advsr Limited Liability Corporation holds 41,998 shares. 4,854 are owned by Old Mutual Customised Solutions (Proprietary). Swiss Bankshares invested in 0% or 96,300 shares. Swiss Bancorp has 1.19 million shares. The insider SOISTMAN FRANCIS S JR sold $872,020.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for with MarketBeat.com's FREE daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE